Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA

robot
摘要生成中

Royce & Associates LP increased its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 54.8% in Q3, now owning 345,507 shares valued at $2,004,000. Other institutional investors have also adjusted their holdings, with institutional ownership now at 86.39%. Despite some negative sentiment regarding earnings forecasts, analysts have a “Moderate Buy” rating for Entrada Therapeutics with a consensus target price of $18.50.

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论